| Document |
Document Title |
|
JP7369708B2 |
Described herein are compounds that are able to generate oct-2-en-4-one and thus to provide a long-lasting or substantive strawberry odor to an environment. Also described herein is a method of imparting a long-lasting strawberry odor to...
|
|
JP7345806B2 |
To provide an intrinsic black polyimide that has good light shielding performance and excellent mechanical properties, thermal stability, and dielectric properties.An anthraquinone derivative tetraamine monomer has a structure represente...
|
|
JP2023122331A |
To provide an annulene derivative capable of aggregation-induced emission and a method for producing the same.The present invention provides an annulene derivative represented by the general formula (1) (where one of R1 and R2 is an elec...
|
|
JP2023525590A |
The present invention relates to a method of purifying 2-(4'-diethylamino-2'-hydroxybenzoyl)benzoic acid hexyl ester that provides high purity and low content of dialkyl phthalate. [Selection figure] None
|
|
JP7284518B2 |
A compound according to the present invention is characterized by being represented by formula wherein: R1 represents an oxygen atom or a sulfur atom; and each of R2-R6 independently represents a hydrogen atom, an alkyl group having 1-6 ...
|
|
JP7277930B2 |
A phenalene-1-one compound, a photosensitizer composition including the phenalene-1-one compound, an article including the phenalene-1-one compound and/or photosensitizer composition and the use thereof.
|
|
JP2023054399A |
To provide methods for producing trifluoromethyl ketone and pentafluoroethyl ketone in economical, safe and industrial manners.An ester compound represented by the general formula (1) is supplied and mixed with a base and trifluoromethan...
|
|
JP7254297B2 |
Provided are a donor-acceptor type compound having a novel structure and its use.An enamine compound represented by general formula (1)(in the formula:R1represents an electron-withdrawing group;A represents a divalent aromatic hydrocarbo...
|
|
JP2023508469A |
Provided herein are arylcyclohexylamine derivatives and their use in treating psychiatric disorders.
|
|
JP2023017733A |
To provide a novel method for synthesizing 2,4-dimethylpyrimidine-5-ol, a novel intermediate for the method, and use of a product in the synthesis of lemborexant.The present invention provides a novel method for synthesizing 2,4-dimethyl...
|
|
JP2023503271A |
The present disclosure provides salts of (2R,6R)-hydroxynorketamine (HNK), as well as crystalline forms thereof, wherein the salts are derived from malonic acid, salicylic acid, ethanesulfonic acid, glycolic acid, stearic acid, or capric...
|
|
JP7193178B2 |
The present invention relates to an aromatic compound and a preparation method therefor and the use thereof. Specifically, disclosed are a compound as shown in the following general formula (I), or a tautomer, an enantiomer, a diastereom...
|
|
JP2022546456A |
The present disclosure relates to methods for reducing symptoms of major depressive disorder, including suicidal tendencies, in human patients assessed as imminent risk of suicide comprising administering esketamine in addition to standa...
|
|
JP7152403B2 |
The present invention relates to a novel process for the preparation of a nitrogen containing biopolymer-based catalyst and to the novel nitrogen containing biopolymer-based catalysts obtainable by this process. In particular, the invent...
|
|
JP2022543435A |
The present invention relates to a novel compound that enables additional hydrogen bonding with a specific amino acid position of the HAT p300 by structural analysis of histone acetyltransferase (HAT) p300. Since the compound has a remar...
|
|
JP7149073B2 |
The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy a...
|
|
JP2022537336A |
The present invention provides a compound of formula (I) substance (in the formula, R1is an alkyl or alkenyl group having 6 to 20 carbon atoms; R2is H or absent, where O is linked by a double bond; R3is H or acyl group -C(O)R5where R5is ...
|
|
JP2022121805A |
To provide an organic compound that has high chemical stability and can be suitable as a material for an organic light-emitting device.An organic compound is represented by a general formula [1] where R1 to R14 are each independently sel...
|
|
JP2022534425A |
The present invention provides compounds, compositions thereof, and methods of using them. The present invention relates to compounds and methods useful for inhibiting transcription enhancer-associated domains (TEADs). The invention also...
|
|
JP7101293B2 |
The compounds with the general formula I are disclosedwhere n1 is the number of carbon atoms connected to nitrogen atom by a double bond and can take on values of 25 to 41, and where n2 is the number of —CH2— groups and can take on v...
|
|
JP7099754B2 |
Disclosed are a novel hypoxia-inducible factor 1α (HIF-1α) inhibitor, a method of preparing the same, and a pharmaceutical composition for preventing or treating an angiogenesis-related eye disease containing the same as an active ingr...
|
|
JP2022529980A |
Mirror image Method for producing isomerically pure norepinephrine The present invention relates to a novel and efficient method for producing mirror image isomerically pure norepinephrine (also known as noradrenaline) or an adduct there...
|
|
JP7090253B2 |
Provided are an intermetallic compound having high stability and high activity, and a catalyst using the same. A hydrogen storage/release material containing an intermetallic compound represented by formula (1): RTX ... (1) wherein R rep...
|
|
JP2022529324A |
The present invention relates to new inhibitors of the Notch signaling pathway and their use in the treatment and / or prevention of cancer. [Selection diagram] None
|
|
JP2022526213A |
Aspects of the invention are aimed at improving regulatory activity on NMDARs and structurally modified opioids (SMOs) that result in improved PK and PD parameters over existing drugs with NMDAR regulatory activity. Structural modificati...
|
|
JP2022519685A |
A composition comprising a cannabidiol derivative of formula (I) in a pharmaceutical formulation showing increased bioavailability and solubility is described. A cannabidiol derivative of formula (I) and a composition comprising it for u...
|
|
JP2022045366A |
To provide a rare earth complex that is excitable by blue light and has high acid resistance, and a method for manufacturing the rare earth complex.For example, there are provided rare earth complexes which respectively have specific str...
|
|
JP7017208B2 |
1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof.
|
|
JP6999039B2 |
The present invention provides a photoinitiator containing fluorine fluorene oxime esters, a photocurable composition comprising the photoinitiator, and application of the photoinitiator. The photoinitiator has a structure represented by...
|
|
JP2022016389A |
To provide a soil improving agent, a nitrification inhibitor, a fertilizer, and a method of inhibiting nitrification, usable in wide areas from the tropical zone to the temperate zone and using a compound easily obtained from a naturally...
|
|
JP6980269B2 |
To provide a chiral complex which, when used as a catalyst, can make an aromatic boronic acid undergo asymmetric 1,4-addition to a conjugated enone in an aqueous solvent under relatively mild conditions and can be recovered by filtration...
|
|
JP2021533115A |
Compounds and methods for the treatment of neurological or mitochondrial disorders, including epilepsy, are provided. In some embodiments, the compound is substituted 1,4-naphthoquinone.
|
|
JP6974496B2 |
Cannabidiol quinol derivatives of Formula (I) and compositions comprising the same for use in the treatment of conditions that benefit from the inhibition of the HIF prolyl hydroxylases (PHDs) activity are described. Said cannabidiol qui...
|
|
JP2021165277A |
To provide fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amino 1,4-benzoquinone derivatives for treatment of oxidative stress disorders.Disclosed herein are compounds and methods of using such compounds for treating or s...
|
|
JP2021527038A |
A process for the preparation of (2R, 6R) -hydroxynorketamine is provided. The process does not require chromatographic purification and gives (2R, 6R) -hydroxynorketamine in 8 steps with a total yield of 26% and a purity greater than 97%.
|
|
JP2021127302A |
To provide a novel agricultural chemical, particularly a herbicide.The present disclosure provides a cyclopentene compound represented by formula (1) [where A is a hydrogen atom, Z4, Z6, Z8 each denote methyl or the like, Z is Z-1 and Z-...
|
|
JP2021120389A |
To provide a controllable a norketamine compound and a preparation containing the same coping with an identified gap in ketamine treatment of symptoms such as pain, depression, traumatic brain injury, stroke, epilepsy, alcohol dependence...
|
|
JP6922924B2 |
Provided is an efficient and economical production method of a nitrogen-containing compound. A method for producing a compound represented by the formula RC(O)CH=CHNRR, including reacting a compound represented by the following formula (...
|
|
JP6911197B2 |
The present invention discloses a hypocrellin derivative substituted both in a peri-position and in a 2-position by an amino, and a preparation method and use thereof. A general structural formula of the derivative is as represented by f...
|
|
JP6905527B2 |
Disclosed herein are compounds and methods of using such compounds for treating or suppressing oxidative stress disorders, including mitochondrial disorders, impaired energy processing disorders, neurodegenerative diseases and diseases o...
|
|
JP6888550B2 |
Provided is a method for producing an organic compound, wherein the organic compound is an industrially useful compound, and a deodorization step, for removing from a reaction solution odorants that are generated in or remaining after a ...
|
|
JP6886206B1 |
To provide an anthraquinone compound having a maximum absorption in the vicinity of 740 to 800 nm and having excellent solvent solubility. An anthraquinone-based compound represented by the following formula (1). In the formula, R1~ R4Re...
|
|
JP6882990B2 |
The present invention is directed to processes for the preparation of esketamine. The present invention is further directed to processes for the resolution of S-ketamine from a racemic or enantiomerically enriched mixture of ketamine. Th...
|
|
JP6882180B2 |
The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples p...
|
|
JP2020203910A |
To provide a monosubstituted or polysubstituted amphiphilic hypocrellin derivative, and use of the derivative for production of a photosensitizer drug for photodynamic therapy.The amphiphilic hypocrellin derivative is represented by the ...
|
|
JP6792250B2 |
Provided is a production method of kakeromycin and a derivative thereof showing an antifungal activity and cytotoxicity and expected as a new antifungal agent or anticancer agent, by chemical synthesis. A production method of a compound ...
|
|
JP6781596B2 |
To provide a method for producing an onium compound which can produce a specific onium compound with a simple method and a high yield.There is provided a method for producing an onium compound which is any of the following methods (A), (...
|
|
JP2020529445A |
The present invention provides a novel, stable, processable, pharmaceutically acceptable salt form of 2R, 6R-hydroxynorketamine or 2S, 6S-hydroxynorketamine with high water solubility.
|
|
JP6758374B2 |
The present application relates to compounds represented by general formula (I), general formula (II) or general formula (III), and pharmaceutically acceptable salts or hydrates thereof, preparation methods thereof, and pharmaceutical co...
|
|
JP6743237B2 |
The invention relates to photoactive oligomeric aminoketones of general Formulae I and II, for compositions and inks curable with ultraviolet (UV) light. The oligomeric aminoketones of the general Formula I are made by condensation of am...
|
